Abstract:Nowadays, although chemotherapy is an established therapy for breast cancer, the molecular mechanisms of chemotherapy resistance in breast cancer remain poorly understood. This study aims to explore the effects of endoplasmic reticulum stress on autophagy, apoptosis, and chemotherapy resistance in human breast cancer cells by regulating PI3K/AKT/mTOR signaling pathway. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to detect the cell viability of six human breast cancer cell lines (MCF-7, ZR-75-30, T47D, MDA-MB-435s, MDA-MB-453, and MDA-MB-231) treated with tunicamycin (5 μM), after which MCF-7 cells were selected for further experiment. Then, MCF-7 cells were divided into the control (without any treatment), tunicamycin (8 μ), BEZ235 (5 μ), and tunicamycin + BEZ235 groups. Cell viability of each group was testified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Western blotting was applied to determine the expressions of endoplasmic reticulum stress and PI3K/AKT/mTOR pathway–related proteins and autophagy- and apoptosis-related proteins. Monodansylcadaverine and Annexin V–fluorescein isothiocyanate/propidium iodide staining were used for determination of cell autophagy and apoptosis. Furthermore, MCF-7 cells were divided into the control (without any treatment), tunicamycin (5 μM), cisplatin (16 μM), cisplatin (16 μM) + BEZ235 (5 μM), tunicamycin (5 μM) + cisplatin (16 μM), and tunicamycin (5 μM) + cisplatin (16 μM) + BEZ235 groups. Cell viability and apoptosis were also evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and Annexin V–fluorescein isothiocyanate/propidium iodide staining. In MCF-7 cells treated with tunicamycin, cell viability decreased significantly, but PEAK, eIF2, and CHOP were upregulated markedly and p-PI3K, p-AKT, and p-MTOR were downregulated in dose- and time-dependent manners. In the tunicamycin + BEZ235 group, the cell viability was lower and the apoptosis rate was higher than those of the control and monotherapy groups. Compared with the cisplatin group, the tunicamycin + cisplatin group showed a relatively higher growth inhibition rate; the growth inhibition rate substantially increased in the tunicamycin + cisplatin + BEZ235 group than the tunicamycin + cisplatin group. The apoptosis rate was highest in tunicamycin + cisplatin + BEZ235 group, followed by tunicamycin + cisplatin group and then cisplatin group. Our study provide evidence that endoplasmic reticulum stress activated by tunicamycin could promote breast cancer cell autophagy and apoptosis and enhance chemosensitivity of MCF-7 cells by inhibiting the PI3K/AKT/mTOR signaling pathway.

Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via enhancing p53 protein nuclear export

Inhibition of N-Linked Glycosylation by Tunicamycin Enhances Sensitivity to Cisplatin in Human Head-And-Neck Carcinoma Cells

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Tunicamycin Potentiates Cisplatin Anticancer Efficacy Through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma.

Inhibition of Autophagy Enhances Cisplatin Cytotoxicity Through Endoplasmic Reticulum Stress in Human Cervical Cancer Cells

A New Strategy of Promoting Cisplatin Chemotherapeutic Efficiency by Targeting Endoplasmic Reticulum Stress.

Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway

Endoplasmic reticulum stress and quality control in relation to cisplatin resistance in tumor cells

ISG15 Silencing Increases Cisplatin Resistance Via Activating P53-Mediated Cell DNA Repair

Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance.

Er Stress and Autophagy Are Involved in the Apoptosis Induced by Cisplatin in Human Lung Cancer Cells

Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress

Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis

TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis

Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells

Cisplatin Induces HepG2 Cell Cycle Arrest Through Targeting Specific Long Noncoding RNAs and the P53 Signaling Pathway

p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin

TAT‑fused IP3R‑derived Peptide Enhances Cisplatin Sensitivity of Ovarian Cancer Cells by Increasing ER Ca2+ Release

WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.

ABT737 Reverses Cisplatin Resistance by Regulating ER-mitochondria Ca2+ Signal Transduction in Human Ovarian Cancer Cells.

Enhanced Therapeutic Effect of Cisplatin on the Prostate Cancer in Tumor-Bearing Mice by Transfecting the Attenuated Salmonella Carrying a Plasmid Co-Expressing P53 Gene and Mdm2 Sirna